The Christie breast research team is a well-established part of the research and development division, conducting a wide variety of clinical trials that look at new ways of treating breast cancer. This includes a range of phase 1 to 3 studies, many of which involve new drugs, giving existing treatments in new ways or using new devices to administer treatment. 

The team comprises consultant oncologists, clinical research nurses and clinical trial coordinators who work closely together to identify and deliver care to those patients eligible to take part in clinical trials. Our portfolio gives many patients with all stages of breast cancer the opportunity to participate in a clinical trial, often providing additional treatment options and sometimes allowing access to newer treatments.

We have grown since 2002 to become one of the most successful recruiting teams both nationally and internationally in the field of breast cancer. We have played a major part in many significant clinical trials, the results of which have changed standard clinical practice and led to the introduction of new drugs such as Herceptin, TDM1, letrozole, eribulin, palbociclib, ribociclib and bisphosphonates.

Team objectives:

  • To be able to offer a clinical trial to all patients during their breast cancer treatment.
  • To forge close relationships with Sponsors and CROs to enable the team to have access to a variety of clinical trials.
  • Using shared care arrangements to work with local general district hospitals in order to offer clinical trials to patients nearer to their home.
  • To be a world leader in the development of novel therapies that lead to changes in standard practice, thus improving patient outcomes.

For more information about cancer screening and prevention, click here.